Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma
by Zacks Equity Research
Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.
Mirati's (MRTX) Adagrasib Gets Breakthrough Therapy Status
by Zacks Equity Research
Mirati (MRTX) is developing adagrasib as a potential treatment for patients suffering from non-small cell lung cancer with KRAS mutation. An NDA is expected to be filed in the second half of 2021.
Regeneron (REGN)/Sanofi's Libtayo Approved for Additional Indications
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.
Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data
by Kinjel Shah
EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $75.58 in the latest trading session, marking a -0.8% move from the prior day.
AstraZeneca (AZN) Rare Disorder Drug Koselugo Gets EU Nod
by Zacks Equity Research
AstraZeneca's (AZN) Koselugo becomes the first medicine approved in Europe for neurofibromatosis type 1 plexiform neurofibromas.
Bristol Myers' (BMY) Onureg Gets European Commission Approval
by Zacks Equity Research
Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.
Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate
by Zacks Equity Research
Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).
Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal
by Kinjel Shah
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $75.70 in the latest trading session, marking a +0.33% move from the prior day.
Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug
by Zacks Equity Research
Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.
Stock Market News for Jun 11, 2021
by Zacks Equity Research
Benchmarks closed in the green as investors shrugged off inflation report in agreement with the Fed's argument that jump in prices is temporary as demand exceed supply on account of the economy's recovery from the pandemic
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
by Kinjel Shah
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic
by Zacks Equity Research
Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.
Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20
by Zacks Equity Research
Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.
Stock Market News for Jun 8, 2021
by Zacks Equity Research
Benchmarks closed mixed on Monday as investors waited for more economic data to determine the course of economic recovery
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $72.80, marking a -1.77% move from the previous day.
Novo Nordisk (NVO) Semaglutide Gets FDA Nod for Obesity
by Zacks Equity Research
Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.
Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RODM
Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Yervoy for the first-line treatment of malignant pleural mesothelioma.
Why Merck (MRK) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer
Oil & Gas Stock Roundup: BP & Eni's Angola Plans, Shell's Philippine Sale & More
by Nilanjan Choudhury
Apart from BP (BP)-Eni (E) and Royal Dutch Shell (RDS.A), there were news from TOTAL (TOT), Equinor (EQNR) and The Williams Companies (WMB) during the week.
Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer
by Zacks Equity Research
The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.